Vaxcyte develops next-generation pneumococcal vaccines.
Vaxcyte, Inc. (PCVX) is expected to report earnings on Tuesday, November 3, 2026, after the close. Estimated release time 16:08 ET. Consensus EPS estimate is $-2.11.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2025-11-04 | Sep 2025 qtr | $-1.27 | $-1.56 | — | $0 |
| 2025-08-06 | Jun 2025 qtr | $-1.12 | $-1.22 | -8.9% | $0 |
| 2025-05-07 | Mar 2025 qtr | $-1.02 | $-1.04 | -2.0% | $0 |
| 2025-02-25 | Dec 2024 qtr | $-1.16 | $-1.12 | +3.4% | $0 |
| 2024-11-05 | Sep 2024 qtr | $-1.10 | $-0.83 | — | $0 |
| 2024-08-06 | Jun 2024 qtr | $-0.98 | $-1.10 | -12.8% | $0 |
| 2024-05-08 | Mar 2024 qtr | $-1.13 | $-0.85 | — | $0 |
| 2024-02-27 | Dec 2023 qtr | $-0.90 | $-1.73 | — | $0 |
PCVX has beaten consensus EPS in 1 of its last 4 scored quarters.
See PCVX on the live calendar →